Proactive Toxicity Management and Dose Modification in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, the discussion centers on proactive toxicity management strategies in EGFR mutated metastatic non-small cell lung cancer. Dr. Rotow outlines practical approaches to preventing and managing dermatologic and other class related adverse events associated with EGFR targeted therapies. She emphasizes early patient education, structured prophylactic regimens, close follow up during treatment initiation, and prompt intervention to mitigate rash, dry skin, and nail changes. The importance of maintaining adherence through supportive care and setting expectations that treatment is a long term strategy is underscored.

Dr. Singhi then addresses dose interruptions and reductions, noting that treatment modifications are common in clinical practice. He highlights data suggesting that temporary dose interruptions or adjustments, particularly early in therapy, do not necessarily compromise progression free survival. The panel reinforces that preserving quality of life while maintaining efficacy is critical, and that thoughtful dose management supports sustainable, long term treatment in EGFR mutated metastatic non-small cell lung cancer.